Akebia Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
AKBA$0.53+32.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheet
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| (dollars in thousands, except per share amounts) | September 30,2024 | December 31,2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $34,019 | $42,925 |
| Inventories | 20,493 | 15,691 |
| Accounts receivable, net | 32,170 | 39,290 |
| Prepaid expenses and other current assets | 13,438 | 20,243 |
| Total current assets | 100,120 | 118,149 |
| Property and equipment, net | 2,533 | 3,629 |
| Operating right-of-use assets | 9,300 | 12,416 |
| Intangible asset, net | 9,011 | 36,042 |
| Goodwill | 59,044 | 59,044 |
| Other long-term assets | 27,134 | 12,423 |
| Total assets | $207,142 | $241,703 |
| Liabilities and stockholders' deficit | ||
| Current liabilities: | ||
| Accounts payable | $13,494 | $14,635 |
| Accrued expenses and other current liabilities | 52,215 | 67,735 |
| Current portion of long-term debt | — | 17,500 |
| Total current liabilities | 65,709 | 99,870 |
| Long-term deferred revenue | — | 43,296 |
| Long-term operating lease liabilities | 4,937 | 8,947 |
| Long-term debt, net | 38,355 | 17,183 |
| Liability related to settlement royalties | 47,731 | — |
| Liability related to sale of future royalties, net of current portion | 52,381 | 54,013 |
| Working Capital Fund liability | 40,203 | 40,093 |
| Warrant liability | 3,501 | — |
| Other long-term liabilities | 4,727 | 8,885 |
| Total liabilities | 257,544 | 272,287 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' deficit: | ||
| Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 | — | — |
| Common stock $0.00001 par value; 350,000,000 shares authorized at September 30, 2024 and December 31, 2023; 211,542,122 and 194,582,539 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 2 | 2 |
| Additional paid-in capital | 1,605,146 | 1,578,358 |
| Accumulated other comprehensive income | 6 | 6 |
| Accumulated deficit | (1,655,556) | (1,608,950) |
| Total stockholders' deficit | (50,402) | (30,584) |
| Total liabilities and stockholders' deficit | $207,142 | $241,703 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.